Last $0.40 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:30 PM 09/11/14 All times are local (Market data is delayed by at least 15 minutes).

unilife corp-cdi (UNISZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/14 - $0.80
52 Week Low
09/5/14 - $0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UNILIFE CORP-CDI (UNISZ)

Related News

No related news articles were found.

unilife corp-cdi (UNISZ) Related Businessweek News

View More BusinessWeek News

unilife corp-cdi (UNISZ) Details

Unilife Corporation designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The company offers Unifill, a pre-filled syringe with integrated, automatic, and user-controlled retraction; Unifill Finesse, an integrated, automatic, and user-controlled retraction with standard plunger seal and plunger rod; Unifill Select, which allows an end-user to select and attach a needle at the time of injection; Unifill Nexus that is equipped with an integrated luer adapter to provide connectivity with needleless luer access devices; and Unifill Allure, which combines universal luer connectivity with automatic, user-controlled needle retraction. It also provides ReadyToGo platform of wearable injectors designed for pre-filled, disposable devices that can be worn by a patient over periods during the subcutaneous injection of therapies; LISA smart reusable auto-injector; and RITA disposable auto-injector, an ergonomic single-use product. In addition, the company offers drug reconstitution delivery systems, including AutoMix Presto, an automatic reconstitution for single-step mixing and injection; EZMix Genesis, a ventless one-step reconstitution and automatic user-controlled retraction; EZMix Engage, a one step reconstitution to attach and retract a needle; and EZMix Prodigy, a single-barrel reconstitution system with a pre-fillable syringe. Further, it provides ocular delivery systems comprising Ocu-ject for the delivery of microliter sized doses to the eye; Ocu-mix, a dual-chamber syringe platform to reconstitute or mix, and deliver various therapies into the eye with a single injection; and Depot-ject, which places a drug depot into the eye. Additionally, the company offers Micro-ject to optimize the delivery of therapies with microliter doses that are unsuited to conventional device technologies. It serves pharmaceutical and biotechnology companies. The company was founded in 2002 and is headquartered in York, Pennsylvania.

209 Employees
Last Reported Date: 09/15/14
Founded in 2002

unilife corp-cdi (UNISZ) Top Compensated Officers

Chairman, Chief Executive Officer, Member of ...
Total Annual Compensation: $630.0K
President and Chief Operating Officer
Total Annual Compensation: $726.0K
Interim Chief Financial Officer, Chief Accoun...
Total Annual Compensation: $308.0K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $308.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $52.3K
Compensation as of Fiscal Year 2014.

unilife corp-cdi (UNISZ) Key Developments

Unilife Corporation Announces Executive Appointments

Unilife Corporation announced the appointment of Kevin Sellers, a veteran marketing and communications executive at Intel Corporation, to the post of Senior Vice President, Marketing and Communications. Sellers will report to Unilife Chairman and CEO Alan Shortall, with responsibility for investor relations, global marketing and public relations. Prior to joining Unilife, Sellers spent 23 years at Intel Corporation in a variety of key marketing, communications and finance functions. The company also announced the appointment of Mr. Stephen Allan, who has been with the company since 2002, to the position of Senior Vice President of Strategic Planning.

Unilife Corporation Signs Long-Term Commercial Supply Agreement for Use of Depot-ject(TM) Delivery System with Approved Ocular Injection Drug

Unilife Corporation announced the signing of a worldwide 10 year Commercial Supply Agreement with a global pharmaceutical company for the use of the Depot-ject(TM) delivery system with an approved ocular injection therapy. The identity of the pharmaceutical company and its target therapy, which is approved in the U.S and Europe for the treatment of a high prevalence disease of the retina, will remain confidential at this time to protect the commercial interests of the customer. The customer has entered into this arrangement to support the lifecycle management of this approved therapy, which is administered via intravitreal injection into the eye. Unilife anticipates the commercial availability of Depot-ject with this therapy after a 12 to 24 month process of customization and regulatory approval for the drug-device combination.

Unilife Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM

Unilife Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Alan D. Shortall, Chairman, Chief Executive Officer, Member of Strategic Partnerships Committee and Chief Executive Officer of UMSL.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UNISZ:US $0.40 USD 0.00

UNISZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $136.80 USD +2.76
West Pharmaceutical Services Inc $54.19 USD +1.84
Ypsomed Holding AG SFr.85.50 CHF -0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation UNISZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNILIFE CORP-CDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at